Allarity Therapeutics Stock

While it’s the six-letter word that no one wants to hear, on an extremely cynical basis, the growing necessity for cancer research bodes well for biotechnology firms dedicated to eradicating this awful disease. Of course, the COVID-19 pandemic didn’t exactly help the cause on the front of things, with the broader healthcare industry focusing on treatments and vaccines for the SARS-CoV-2 virus.

But as the great intellectual and one of the foremost Founding Fathers Benjamin Franklin stated, an “investment in knowledge pays the best interest.” In other words, efforts to gain greater understanding of a particular concept or discipline rarely go to waste, even if the fruits of those expenditures are not directly associated with the original enterprise. Fortunately, the silver lining in this pandemic is that it sparked downwind benefits for other medical needs.

According to the American Association for Cancer Research, the global health crisis “has enforced innovation and given fresh momentum to clinical trial development in a way that has not happened in cancer research. Cancer research has been disrupted, yet the innovative approaches in adapting to the restrictive environment must be taken forward.”

Sometimes, the worst dilemmas often yield the brightest breakthroughs, which is the main hope undergirding the U.S. listing of oncology specialist Allarity Therapeutics Inc.

When Is the Allarity Therapeutics IPO Date?

Although the major equity indices have absorbed a cascade of crimson due to fears of the omicron variant, one subsegment has witnessed little evidence of slowing down — the initial public offering (IPO) or the first time a private company releases its stock for public investment.

While 2020 was a blistering year for new issues, 2021 is already at an all-time record, with several days to add some bonus swings into the mix. Per a Reuters article in early December, with “weeks left to go till the turn of the year, U.S. IPOs have totaled $301.26 billion in 2021, scorching past last year's record of $168 billion, according to Dealogic.”

Allarity Therapeutics looks set to drive in some more runs with no strikes tallied to its name, although it’s important to consider one important detail. Technically, the biotech firm isn’t an IPO in the strictest sense as its shares previously traded on the Nasdaq First North Growth Market Sweden.

Nevertheless, the company still has a date of Dec. 21 scheduled on the IPO calendar. Recently, Allarity received confirmation of its delisting from Nasdaq First North to essentially make room for its inclusion on the U.S. Nasdaq exchange. Shares will trade under the ticker symbol ALLR.

In some ways, Allarity’s U.S. listing represents a spiritual IPO, presenting similar parallels with over-the-counter stocks receiving a promotion to the main exchanges. For American retail investors, though, ALLR stock is indeed an IPO since this will be their first opportunity to acquire shares in the oncology specialist. As a result, management filed a Form S-1 Registration Statement with the U.S. Securities and Exchange Commission (SEC), following the protocol for traditional public market offerings.

Though the narrative for Allarity’s introduction is an intriguing one on a scientific basis, its timing presents a mixed bag. On the positive front, the company’s novel drug response predictor (DRP) uses messenger-RNA technology “to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients.”

Naturally, companies like Pfizer Inc. (NYSE: PFE) and Moderna Inc. (NASDAQ: MRNA) have proven the viability of mRNA-based innovations to address health crises. Thus, Allarity may attract greater interest among investors who anticipate the expansion of this burgeoning and exciting development.

However, the Federal Reserve’s recently disclosed shift in monetary policy will likely raise borrowing costs in 2022 and beyond, which would disincentivize heavy exposure to risk-on assets. Not only that, both policy implications and suddenly increased worries about the omicron variant’s rapid spread could have an effect. Therefore, due diligence is necessary before wading into ALLR stock.

Allarity Therapeutics Financial History

One of the major frustrations with cancer therapy research is that each individual patient features a unique medical profile. Therefore, many clinical trial participants will simply not pair up effectively with particular therapeutic candidates. However, Allarity’s DRP mechanism — under the broader label of precision medicine or personalized medicine — represents a promising alternative to traditional oncological regimens.

According to the medical journal Frontiers, “Precision medicine or personalized medicine is becoming feasible and widely adopted in cancer treatment due to the availability of multiomics data that comprehensively characterize individual cancer samples. For example, comprehensive multiomics data, like gene expression, copy number variation (CNV), genetic mutation, methylation and proteomics, as well as clinical outcome information of over 20,000 cancer patients across 33 cancer types and subtypes are available in the cancer genome atlas (TCGA) program.”

Simply put, Allarity features the ability to pair cancer patients with appropriate therapies prior to integration of treatments rather than a pray-and-spray methodology that may yield poor outcomes clinically and for the individual patient. Therefore, Allarity’s DRP could help bridge myriad biotech solutions to enter the commercial market quicker than before.

Though incredibly promising, Frontiers warns that “it remains challenging to integrate and interpret the diverse and large number of data points in the high-dimensional multiomics data in a biologically meaningful manner.” For Allarity, this headwind has translated to a conspicuous lack of fiscal success.

From the company’s own IPO prospectus, Allarity features a “limited operating history” and has “never generated any revenues other than from research grants” and a limited number of development agreements regarding its DRP biomarker. Therefore, management warns that it may be “difficult to evaluate the success of our business to date and to assess our future viability.”

In addition, Allarity notes that “Clinical trials are very expensive, time-consuming and difficult to design and implement and involve uncertain outcomes. Furthermore, results of earlier preclinical studies and clinical trials may not be predictive of results of future preclinical studies or clinical trials.” To put it bluntly, through acquiring ALLR stock, you are subsidizing Allarity’s ambitions.

Finally, before you do anything, you should assess the biotech’s cash flow statement. Specifically, the main reason for its robust cash tally for the nine months ending Sept. 30, 2021, is proceeds from share issuance. While that might address near-term financial needs, too much distribution could easily dilute your holdings.

Allarity Therapeutics Potential

If you could rank IPOs by their industry potential, you’d be hard pressed to find something more compelling than Allarity Therapeutics. Thanks to digitalization technologies and advancements in artificial intelligence, e-commerce platforms have become almost alarmingly effective in connecting consumers with appropriate products based on their web-surfing patterns.

Effectively, this brokering to promote efficient and desirable outcomes sits at the heart of ALLR’s public offering. Through the latest medical innovations, Allarity can direct clinical resources to where they may be most effective, thus improving results across the board.

However, as mentioned earlier, crystallizing the various innovations of precision medicine into consistent standardized outcomes remains elusive. That’s not just an industry headwind but a company-specific one. Unfortunately, Allarity’s less-than-robust financial picture demands extensive due diligence.

While the biotech may be promising, it needs to be a going concern. Securing critical funding may be just as much a challenge as pushing its therapies forward. With the unforgiving and unpredictable clinical arena, no one can say for certain where ALLR stock will end up.

How to Buy Allarity Therapeutics IPO (ALLR) Stock

With ALLR soon set to make its U.S. debut, interested parties must acquire shares at the open, advantaging those who know how to buy stocks. For a refresher, follow the steps below.

Step 1: Pick a brokerage.

With the best brokers competing on similar financial incentives, you can narrow your search to platforms that ideally suit your needs.

Step 2: Decide how many shares you want.

The riskiest IPOs involve speculative biotechs. Therefore, choose a balanced share count if you want to participate.

Step 3: Choose your order type.

Before trading, learn these market concepts.

• Bid: The buyer’s best offer for a stock.
• Ask: The seller’s lowest acceptable price.
• Spread: The difference between the bid-ask price, the spread indicates market risk as this is also the profit margin for market makers.
• Limit order: Buy or sell requests at a predetermined price, limit orders provide transparency but no execution guarantees.
• Market order: Market orders guarantee fulfillment but only at the current rate.
• Stop-loss order: Stop-loss orders automatically exit your position at either a predetermined price or anything lower.
• Stop-limit order: Stop-limit orders only leave positions at a specified price, but they also carry non-fulfillment risks.

Step 4: Execute your trade.

Follow these steps to execute a market order:

1. Select your action type (buy or sell).
2. Enter the shares you want to acquire (or sell).
3. Hit the Buy (or Sell) button.

Follow the same sequence for limit orders (but include your execution price).

ALLR Restrictions for Retail Investors

Review the Financial Industry Regulatory Authority (FINRA) rules on restricted persons before participating in an IPO. Don’t engage if you have privileged information.

ALLR Pre-IPO

While ALLR is not available for pre-IPO purchase, Freedom Finance offers early bird access for some of the most anticipated public debuts.

High Potential Sailing into Strong Winds

Thanks to groundbreaking innovations in precision therapies, Allarity could fill the gap between cancer treatment potential and reality. However, prospective investors of ALLR stock must also keep abreast of financial realities, which can easily sour a bright idea.